Amoéba 2021 results: further development of biocidal and biocontrol applications

In France, AMOEBA, producer of a biological biocide capable of eliminating bacterial risk in water and human wounds, and a biocontrol product for plant protection, still in the development phase, updated the schedule for its various regulatory files related to the biocidal application in Europe and noted that the company is preparing to carry out a new field test campaign for its biocontrol product in 2022.

Other updates include:

• For the biocidal application (active substance: amoeba Willaertia magna C2c Maky viable) in Europe, the Maltese authority (MCCAA) had committed to submit the evaluation report of the active substance to the company by 31 March 2022 (see Press Release of 15 November 2021). In March 2022, the MCCAA informed Amoéba that a few more weeks would be needed to fully finalise the assessment report.
• Concerning the biocontrol application (active substance: Willaertia magna C2c Maky lysate) in Europe, the Austrian Authority (AGES) had informed the Company that the evaluation report should be finalised by the end of March 2022 (see Press Release of 14 December 2021). In March 22 AGES informed Amoeba that, due to the exceptional pandemic situation in Austria, many expert evaluators were incapacitated or in quarantine, leading to an extension of the evaluation by a few weeks.
• For the other applications under evaluation (biocide in the USA and Canada; biocontrol in the USA and Brazil), the information provided in the Press Release of 14 December 2021 is still valid.

In addition to existing applications (biocide and biocontrol), Amoeba receives numerous requests to integrate its solution into new fields of operation. A strict scientific evaluation of these opportunities is carried out permanently by our laboratory and external expert laboratories.